327 related articles for article (PubMed ID: 32321898)
21. Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
Neff G; Zachry W
Pharmacoeconomics; 2018 Jul; 36(7):809-822. PubMed ID: 29651649
[TBL] [Abstract][Full Text] [Related]
22. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
[TBL] [Abstract][Full Text] [Related]
23. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of rifaximin versus lactulose for reducing the recurrence of overt hepatic encephalopathy and hopitalizations in cirrhosis.
Irimia R; Trifan A
Rev Med Chir Soc Med Nat Iasi; 2012; 116(4):1021-7. PubMed ID: 23700882
[TBL] [Abstract][Full Text] [Related]
25. Preferential usage of rifaximin for the treatment of hydrogen-positive smallintestinal bacterial overgrowth.
Barkin JA; Keihanian T; Barkin JS; Antequera CM; Moshiree B
Rev Gastroenterol Peru; 2019; 39(2):111-115. PubMed ID: 31333225
[TBL] [Abstract][Full Text] [Related]
26. How to Test and Treat Small Intestinal Bacterial Overgrowth: an Evidence-Based Approach.
Rezaie A; Pimentel M; Rao SS
Curr Gastroenterol Rep; 2016 Feb; 18(2):8. PubMed ID: 26780631
[TBL] [Abstract][Full Text] [Related]
27. Chronic prostatitis and small intestinal bacterial overgrowth: effect of rifaximin.
Weinstock LB; Geng B; Brandes SB
Can J Urol; 2011 Aug; 18(4):5826-30. PubMed ID: 21854715
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care.
Bohra A; Worland T; Hui S; Terbah R; Farrell A; Robertson M
World J Gastroenterol; 2020 May; 26(18):2221-2231. PubMed ID: 32476788
[TBL] [Abstract][Full Text] [Related]
29. Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States.
Tapper EB; Essien UR; Zhao Z; Ufere NN; Parikh ND
J Hepatol; 2022 Aug; 77(2):377-382. PubMed ID: 35367057
[TBL] [Abstract][Full Text] [Related]
30. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
[TBL] [Abstract][Full Text] [Related]
31. Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes.
Rahimi RS; Brown KA; Flamm SL; Brown RS
Am J Med; 2021 Nov; 134(11):1330-1338. PubMed ID: 34242619
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy.
Jesudian AB; Ahmad M; Bozkaya D; Migliaccio-Walle K
J Manag Care Spec Pharm; 2020 Jun; 26(6):750-757. PubMed ID: 32463782
[TBL] [Abstract][Full Text] [Related]
33. Total Bilirubin Is Associated with Small Intestinal Bacterial Overgrowth in Diarrhea Predominant Irritable Bowel Syndrome.
Kim SY; Seo YS; Lee ES; Kim KN
Ann Clin Lab Sci; 2019 May; 49(3):344-352. PubMed ID: 31308034
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
Ahire K; Sonawale A
J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
[TBL] [Abstract][Full Text] [Related]
35. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
[TBL] [Abstract][Full Text] [Related]
36. Hepatic encephalopathy - recent advances in treatment and diagnosis.
Nardelli S; Gioia S; Faccioli J; Riggio O; Ridola L
Expert Rev Gastroenterol Hepatol; 2023 Mar; 17(3):225-235. PubMed ID: 36843291
[TBL] [Abstract][Full Text] [Related]
37. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2017 May; 5(5):CD001939. PubMed ID: 28518283
[TBL] [Abstract][Full Text] [Related]
38. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Sep; (9):CD001939. PubMed ID: 26377410
[TBL] [Abstract][Full Text] [Related]
39. Branched-chain amino acids for people with hepatic encephalopathy.
Gluud LL; Dam G; Les I; Córdoba J; Marchesini G; Borre M; Aagaard NK; Vilstrup H
Cochrane Database Syst Rev; 2015 Feb; (2):CD001939. PubMed ID: 25715177
[TBL] [Abstract][Full Text] [Related]
40. [Pay more attention to hepatic encephalopathy].
Labenz J
MMW Fortschr Med; 2014 Feb; 156(2):60-1. PubMed ID: 24934059
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
